Disease Landscape and Forecast Insights

A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the impact…

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals…

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…

Renal anemia is a common complication of chronic kidney disease (CKD). Although there are treatments for the disease, physicians, patients, and healthcare systems have concerns about their…

Abstract here

Abstract here

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 520 currently available and novel biosimilar products, detailing…

The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of Roche’s Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, biosimilars of…

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…

The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilars developers must ensure that they are equipped with the necessary…